LongEGF and LongTGF-α
EGF / Betacellulin / TGF-α Family
IGF Binding Proteins （IGFBP）
GroPep was founded in 1988 by CSIRO （the Australian Government's Commonwealth Scientific and Industrial Research Organisation） and the University of Adelaide.
In December 2006 GroPep was acquired by the Danish company Novozymes A/S and became Novozymes GroPep Limited.
Continued strong financial performance with record growth in net profit before tax to $3.1 million, more than triple that reported in 2004. One-off tax benefits lifted profit, after tax to $6.4 million. Marketing arrangements for Cell Culture Products were transferred from CSL Limited to Sigma-Aldrich Corporation （USA） by CSL's sale of its JRH Biosciences subsidiary.
Achieved a significant turnaround in financial performance to record a profit of $1.0 million and operating cash flow of $3.8 million. Commenced a $3 million facility upgrade to support our rapidly growing cell culture business.
Biotech Australia assets disposed of and on-going business consolidated to Adelaide.
GroPep acquired assets and on-going business of Sydney-based Biotech Australia Pty. Ltd.
GroPep launched a new clinical trial at the Peter MacCallum Cancer Institute in Melbourne for a chemotherapy side-effect treatment.
Pre-clinical development of a treatment for recurrent miscarriage and other unexplained infertility conditions in humans was begun.
GroPep is a founding shareholder of TGR BioSciences Pty Ltd, which was incorporated in June 2001.
GroPep relocated staff and operations to a manufacturing, R&D and administration building at Thebarton in suburban Adelaide.
GroPep successfully launches its business on the Australian Stock Exchange （Code: GRO）.
GroPep became a founding shareholder in Primegro® Ltd, a company established to commercialise agricultural and veterinary uses of growth factor technology.
GroPep established its Pharmaceutical Drug Development business to develop pharmaceutical products through Phase I and II clinical trials.
The Australian Government renewed The Cooperative Research Centre （CRC） grant for a further seven years.
GroPep and Flinders University joined the original partners of the CRC, and GroPep gained exclusive rights to commercialise inlectual property developed by staff in the CRC.
GroPep commenced the production of its new recombinant variant of IGF-I （LONG®R³IGF-I）. This product is marketed as a replacement for insulin in cell culture media, and is the basis of the Company's Cell Culture business.
GroPep commenced the manufacture of IGFs and related reagents and marketed them worldwide for research purposes. This is the basis of the Company's Biotechnology Reagents business.
GroPep becomes the commercial arm of the Australian Government funded 'Cooperative Research Centre （CRC） for Tissue Growth and Repair'. Commonwealth Scientific and Industrial Research Organisation （CSIRO）, University of Adelaide, Child Health Research Institute （CHRI） and Dairy Research and Development Corporation （DRDC） held equity in both the CRC and GroPep.
GroPep was founded to commercialise inlectual property relating to a novel insulin-like growth factor （IGF） developed through a scientific collaboration between the Commonwealth Scientific and Industrial Research Organisation （CSIRO） and the University of Adelaide.